Scott Wilkie

2.0k total citations
25 papers, 1.6k citations indexed

About

Scott Wilkie is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Molecular Biology. According to data from OpenAlex, Scott Wilkie has authored 25 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 8 papers in Radiology, Nuclear Medicine and Imaging and 6 papers in Molecular Biology. Recurrent topics in Scott Wilkie's work include CAR-T cell therapy research (10 papers), Monoclonal and Polyclonal Antibodies Research (8 papers) and Antibiotics Pharmacokinetics and Efficacy (4 papers). Scott Wilkie is often cited by papers focused on CAR-T cell therapy research (10 papers), Monoclonal and Polyclonal Antibodies Research (8 papers) and Antibiotics Pharmacokinetics and Efficacy (4 papers). Scott Wilkie collaborates with scholars based in United Kingdom, United States and Australia. Scott Wilkie's co-authors include John Maher, David M. Davies, Sjoukje J. C. van der Stegen, S. Burbridge, May CI van Schalkwyk, Suzanne A. Eccles, Carol Box, Stephen J. Mather, Julie Foster and Steve Hobbs and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and The Journal of Immunology.

In The Last Decade

Scott Wilkie

23 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Scott Wilkie United Kingdom 14 1.2k 539 502 475 368 25 1.6k
Liza B. John Australia 16 1.7k 1.4× 612 1.1× 389 0.8× 1.2k 2.6× 399 1.1× 27 2.4k
Norihiro Watanabe United States 22 1.6k 1.4× 704 1.3× 494 1.0× 780 1.6× 647 1.8× 53 2.0k
Christel Devaud Australia 16 1.4k 1.2× 441 0.8× 292 0.6× 1.0k 2.1× 322 0.9× 27 1.9k
Barry Flutter United Kingdom 17 889 0.7× 323 0.6× 210 0.4× 1.2k 2.5× 244 0.7× 23 1.7k
Kunhong Zhong China 15 638 0.5× 672 1.2× 170 0.3× 338 0.7× 179 0.5× 32 1.4k
Yang Feng United States 10 921 0.8× 365 0.7× 270 0.5× 415 0.9× 265 0.7× 25 1.2k
Natalia Lapteva United States 21 1.1k 0.9× 517 1.0× 141 0.3× 1.1k 2.3× 288 0.8× 45 1.7k
Meng Wu China 12 513 0.4× 485 0.9× 190 0.4× 463 1.0× 130 0.4× 31 1.2k
Kristen Fousek United States 11 703 0.6× 298 0.6× 198 0.4× 431 0.9× 122 0.3× 21 1.1k
Stefanie Koristka Germany 27 1.4k 1.2× 482 0.9× 662 1.3× 617 1.3× 305 0.8× 60 1.7k

Countries citing papers authored by Scott Wilkie

Since Specialization
Citations

This map shows the geographic impact of Scott Wilkie's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Scott Wilkie with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Scott Wilkie more than expected).

Fields of papers citing papers by Scott Wilkie

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Scott Wilkie. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Scott Wilkie. The network helps show where Scott Wilkie may publish in the future.

Co-authorship network of co-authors of Scott Wilkie

This figure shows the co-authorship network connecting the top 25 collaborators of Scott Wilkie. A scholar is included among the top collaborators of Scott Wilkie based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Scott Wilkie. Scott Wilkie is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
Petrovic, Roseanna M., Scott Wilkie, & John Maher. (2016). Abstract A082: Developing a PD-1 based inhibitory chimeric antigen receptor (ICAR) for co-expression, to overcome off-tumor toxicity when targeting ErbB2 using engineered T cells. Cancer Immunology Research. 4(1_Supplement). A082–A082. 3 indexed citations
4.
Kazlauskaite, Agne, R.J. Martinez-Torres, Scott Wilkie, et al.. (2015). Binding to serine 65‐phosphorylated ubiquitin primes Parkin for optimal PINK 1‐dependent phosphorylation and activation. EMBO Reports. 16(8). 939–954. 199 indexed citations
5.
Parente‐Pereira, Ana C., Scott Wilkie, Sjoukje J. C. van der Stegen, David M. Davies, & John Maher. (2014). Use of retroviral-mediated gene transfer to deliver and test function of chimeric antigen receptors in human T-cells. Journal of Biological Methods. 1(2). 1–1. 5 indexed citations
6.
Wilkie, Scott, et al.. (2013). A Hard Step for Soft-Moc. International Transfer Pricing Journal. 20(5). 1 indexed citations
7.
Davies, David M., Julie Foster, Sjoukje J. C. van der Stegen, et al.. (2012). Flexible Targeting of ErbB Dimers That Drive Tumorigenesis by Using Genetically Engineered T Cells. Molecular Medicine. 18(4). 565–576. 95 indexed citations
8.
Wilkie, Scott, May CI van Schalkwyk, Steve Hobbs, et al.. (2012). Dual Targeting of ErbB2 and MUC1 in Breast Cancer Using Chimeric Antigen Receptors Engineered to Provide Complementary Signaling. Journal of Clinical Immunology. 32(5). 1059–1070. 399 indexed citations
9.
Parente‐Pereira, Ana C., Jerome Burnet, David H. Ellison, et al.. (2011). Trafficking of CAR-Engineered Human T Cells Following Regional or Systemic Adoptive Transfer in SCID Beige Mice. Journal of Clinical Immunology. 31(4). 710–718. 87 indexed citations
10.
Wilkie, Scott, S. Burbridge, Laura Chiapero-Stanke, et al.. (2010). Selective Expansion of Chimeric Antigen Receptor-targeted T-cells with Potent Effector Function using Interleukin-4. Journal of Biological Chemistry. 285(33). 25538–25544. 157 indexed citations
11.
Wilkie, Scott, Gianfranco Picco, Julie Foster, et al.. (2008). Retargeting of Human T Cells to Tumor-Associated MUC1: The Evolution of a Chimeric Antigen Receptor. The Journal of Immunology. 180(7). 4901–4909. 273 indexed citations
12.
Rees, Christine A., et al.. (2003). Dosing regimen and hematologic effects of pentoxifylline and its active metabolites in normal dogs.. PubMed. 4(2). 188–96. 8 indexed citations
13.
Rees, Christine A., D.M. Boothe, & Scott Wilkie. (2002). Therapeutic response to pentoxifylline and its active metabolites in dogs with dermatomyositis. Veterinary Dermatology. 13(4). 211–229. 3 indexed citations
14.
Wilkie, Scott, et al.. (2002). RB activation defect in tumor cell lines. Proceedings of the National Academy of Sciences. 99(22). 14200–14205. 41 indexed citations
15.
Wilkie, Scott, et al.. (2001). Time course of enrofloxacin and its active metabolite in peripheral leukocytes of dogs.. PubMed. 2(4). 334–44. 13 indexed citations
16.
Buchanan, Charles, et al.. (2001). Pharmacokinetics of the bovine formulation of enrofloxacin (Baytril 100) in horses.. PubMed. 2(2). 129–34. 10 indexed citations
17.
Boothe, D.M., Albert Boeckh, Harry W. Boothe, & Scott Wilkie. (2001). Tissue concentrations of enrofloxacin and ciprofloxacin in anesthetized dogs following single intravenous administration.. PubMed. 2(2). 120–8. 13 indexed citations
18.
Ellis, Mark, et al.. (1998). pRB phosphorylation mutants reveal role of pRB in regulating S phase completion by a mechanism independent of E2F. Oncogene. 17(17). 2177–2186. 73 indexed citations
19.
Petrella, Eugene C., Scott Wilkie, Craig A. Smith, Alton C. Morgan, & Carl‐Wilhelm Vogel. (1987). Antibody conjugates with cobra venom factor. Journal of Immunological Methods. 104(1-2). 159–172. 27 indexed citations
20.
Vogel, Carl‐Wilhelm, Scott Wilkie, & A C Morgan. (1985). In Vivo Studies with Covalent Conjugates of Cobra Venom Factor and Monoclonal Antibodies to Human Tumors. Hämatologie und Bluttransfusion. 29. 514–517. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Liza B. John Breakdown of academic impact, for papers by Norihiro Watanabe Breakdown of academic impact, for papers by Christel Devaud Breakdown of academic impact, for papers by Barry Flutter Breakdown of academic impact, for papers by Kunhong Zhong Breakdown of academic impact, for papers by Yang Feng Breakdown of academic impact, for papers by Natalia Lapteva Breakdown of academic impact, for papers by Meng Wu Breakdown of academic impact, for papers by Kristen Fousek Breakdown of academic impact, for papers by Stefanie Koristka
Rankless by CCL
2026